Advertisement


Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

2024 ASCO Annual Meeting

Advertisement

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
COMBI-AD trial is a randomized phase three clinical trial of adjuvant dabrafenib combined with trametinib versus placebo for resected stage three BRAF mutated melanoma. The final analysis, the long-term data and the overall survival data were presented and show a durable and sustained benefit in terms of relapse-free survival when patients received dabrafenib plus trametinib versus placebo. There was a 48% reduction in the risk of recurrence with nearly 10 years of follow-up. In fact, the median follow-up was 100 months for dabrafenib plus trametinib and 82 months for placebo, and the maximum follow-up was 125 months. So when we look at the relapse-free survival and look at the eight-year relapse-free survival landmark, we saw 50% for dabrafenib and trametinib, which was much higher than the 35% we saw for placebo. Again, we saw a sustained and durable improvement in the distant metastasis-free survival with a hazard ratio of 0.56, that's a 44% reduction in the risk of distant metastasis at first recurrence. So therefore, the two major endpoints were statistically significant with confidence intervals that did not cross one demonstrating this durable and sustained impact of adjuvant dabrafenib-trametinib. The overall survival showed a separation of the Kaplan-Meier curves with a 20% reduction in the risk of death from any cause using adjuvant dabrafenib-trametinib versus placebo. This is a hazard ratio of 0.80. However, the confidence interval just nudged over one, 1.01, and the P-value is 0.063 so this was not statistically significant. We will not see an adjuvant trial which has any separation of the Kaplan-Meier curves. So this is substantial for the modern era of melanoma treatments when we know that we can cure patients in the advanced setting to see any separation of the overall survival curves in the stage three setting. What was remarkable is if we looked at the subgroup of V600E, they seem to benefit the most in terms of overall survival. The dabrafenib-trametinib hazard ratio versus placebo was 0.75, that's a 25% risk reduction terms of death using adjuvant dabrafenib and trametinib for those with the V600E and that was 91% of the trial population. However, for V600K, which was a small subgroup, there was a reversal, the placebo arm seemed to do better than dabrafenib-trametinib, but we have to exercise caution with only 40 and 37 patients in each arm for that analysis, but it does suggest that the main benefit seems to be in patients with V600E melanoma. Interestingly, the relapse-free survival benefit with dabrafenib and trametinib was seen for both V600E, and V600K. So it was only the overall survival where we saw really the substantial benefit in the V600E. So what does this mean for the future? It means that we have a treatment that can be used for BRAF V600 mutated patients for adjuvant therapy for resected stage three. There were no irreversible toxicities with this long-term follow-up data, and we saw a sustained and durable impact on the relapse-free survival, the distant metastasis-free survival, and we did see a numerical improvement in the overall survival as well as the melanoma-specific survival, a very important endpoint as we cure more patients with melanoma.

Related Videos

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Lung Cancer

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).

Advertisement

Advertisement




Advertisement